Overexpression of Rad51 Predicts Poor Prognosis and Silencing of Rad51 Increases Chemo-sensitivity to Doxorubicin in Neuroblastoma

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2019 Oct 22

PMID 31632548

Citations 12

Authors

Yonghu Xu

Kai Chen

Yuanxia Cai

Cheng Cheng

Zihan Zhang

Guofeng Xu

Affiliations

Soon will be listed here.

Abstract

Outcome for children with high-risk neuroblastoma (NB) remains suboptimal. Recurrence and metastasis caused by chemo-resistance is an underlying mechanism contributing to the poor prognosis. Aberrant expression of Rad51 is implicated in both radio- and chemo-sensitivity in many human malignancies. However, its clinical significance and relationship with chemo-sensitivity in NB remain undefined. In this study, Rad51 expression was first evaluated in 70 surgically resected NB specimens by immunochemistry using tissue microarray and the correlation with clinic-pathologic features including survival was assessed. We then conducted microarray-based search with the Tumor Neuroblastoma public datasets to validate the immunochemistry results. Furthermore, the role of Rad51 in drug sensitivity was studied by using short hairpin RNA in the human NB SK-N-BE(2) and SH-SY5Y cells with treatment of doxorubicin. Our findings demonstrated for the first time that Rad51 is a prognostic marker in NB and down-regulation of Rad51 can lead to chemo-sensitizing effect in human NB cells.

Citing Articles

Copy-number dosage regulates telomere maintenance and disease-associated pathways in neuroblastoma.

Burkert M, Blanc E, Thiessen N, Weber C, Toedling J, Monti R iScience. 2024; 27(10):110918.

PMID: 39635126 PMC: 11615189. DOI: 10.1016/j.isci.2024.110918.

RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma.

Tsai Y, Chan L, Chen Y, Su C, Hsu C, Wang Y Cancer Cell Int. 2023; 23(1):231.

PMID: 37798649 PMC: 10552296. DOI: 10.1186/s12935-023-03071-w.

A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells.

Carusillo A, Haider S, Schafer R, Rhiel M, Turk D, Chmielewski K Nucleic Acids Res. 2023; 51(9):4660-4673.

PMID: 37070192 PMC: 10201422. DOI: 10.1093/nar/gkad255.

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy.

Matias-Barrios V, Dong X Pharmaceuticals (Basel). 2023; 16(1).

PMID: 36678591 PMC: 9866718. DOI: 10.3390/ph16010094.

Canine Mammary Tumor Cell Lines Derived from Metastatic Foci Show Increased RAD51 Expression but Diminished Radioresistance via p21 Inhibition.

Shimakawa K, Ochiai K, Hirose S, Tanabe E, Michishita M, Sakaue M Vet Sci. 2022; 9(12).

PMID: 36548864 PMC: 9784702. DOI: 10.3390/vetsci9120703.

References

de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P . Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer. 2006; 48(3):311-7. DOI: 10.1002/pbc.20853. View

Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G . A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med. 2013; 5(3):353-65. PMC: 3598077. DOI: 10.1002/emmm.201201760. View

Zhang Q, Zhang Q, Jiang X, Ye Y, Liao H, Zhu F . Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN. Theranostics. 2019; 9(4):986-1000. PMC: 6401405. DOI: 10.7150/thno.30199. View

Wang Y, Chen K, Cai Y, Cai Y, Yuan X, Wang L . Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma. J Exp Clin Cancer Res. 2017; 36(1):111. PMC: 5559827. DOI: 10.1186/s13046-017-0581-6. View

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S . Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther. 2009; 8(1):203-13. DOI: 10.1158/1535-7163.MCT-08-0959. View

Benson F, Baumann P, West S . Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature. 1998; 391(6665):401-4. DOI: 10.1038/34937. View

Li Y, Yu H, Luo R, Zhang Y, Zhang M, Wang X . Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma. J Surg Oncol. 2011; 104(6):617-22. DOI: 10.1002/jso.22018. View

Pugh T, Morozova O, Attiyeh E, Asgharzadeh S, Wei J, Auclair D . The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-84. PMC: 3682833. DOI: 10.1038/ng.2529. View

10.

Pearson A, Pinkerton C, Lewis I, Imeson J, Ellershaw C, Machin D . High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008; 9(3):247-56. DOI: 10.1016/S1470-2045(08)70069-X. View

11.

Chen Q, Cai D, Li M, Wu X . The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma. Oncol Rep. 2017; 38(2):767-774. PMC: 5561999. DOI: 10.3892/or.2017.5724. View

12.

Pinto N, Applebaum M, Volchenboum S, Matthay K, London W, Ambros P . Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015; 33(27):3008-17. PMC: 4567703. DOI: 10.1200/JCO.2014.59.4648. View

13.

Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L . DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 2000; 19(23):2791-5. DOI: 10.1038/sj.onc.1203578. View

14.

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

15.

Brunen D, de Vries R, Lieftink C, Beijersbergen R, Bernards R . PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma. Mol Cancer Ther. 2018; 17(4):849-857. DOI: 10.1158/1535-7163.MCT-17-0868. View

16.

Xu Z, Loignon M, Han F, Panasci L, Aloyz R . Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther. 2005; 314(2):495-505. DOI: 10.1124/jpet.105.084053. View

17.

Qiao G, Wu Y, Yang X, Zhong W, Xie D, Guan X . High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer. 2005; 93(1):137-43. PMC: 2361489. DOI: 10.1038/sj.bjc.6602665. View

18.

Keshelava N, Zuo J, Waidyaratne N, Triche T, Reynolds C . p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol. 2000; 35(6):563-8. DOI: 10.1002/1096-911x(20001201)35:6<563::aid-mpo15>3.0.co;2-j. View

19.

Gu Y, Lv F, Xue M, Chen K, Cheng C, Ding X . The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation. J Exp Clin Cancer Res. 2018; 37(1):258. PMC: 6203192. DOI: 10.1186/s13046-018-0931-z. View

20.

Michaelis M, Selt F, Rothweiler F, Loschmann N, Nusse B, Dirks W . Aurora kinases as targets in drug-resistant neuroblastoma cells. PLoS One. 2014; 9(9):e108758. PMC: 4182628. DOI: 10.1371/journal.pone.0108758. View